Head-to-head evidence
TQH3906 vs zasocitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
TQH3906
Developed by Sino Biopharmaceutical
NCT06542614 · Phase 2 · completed
This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.
Next expected readout: September 2027 · NCT07724366 (registry estimate)
zasocitinib
Developed by Takeda Pharmaceutical Company
NCT06108544 · Phase 3 · completed
This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT07752108 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: TQH3906's landscape · zasocitinib's landscape